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Bacterial permeability family member A1 (BPIFA1), also known as short palate, lung, and
nasal epithelium clone 1 (SPLUNC1), is a protein involved in the antiinflammatory
response. The goal of this study was to determine whether BPIFA1 expression in asthmatic
airways is regulated by genetic variations, altering epithelial responses to type 2 cytokines
(e.g., IL-13). Nasal epithelial cells from patients with mild to severe asthma were collected
from the National Heart, Lung, and Blood Institute Severe Asthma Research Program
centers, genotyped for rs750064, and measured for BPIFA1. To determine the function of
rs750064, cells were cultured at air-liquid interface and treated with IL-13 with or without
recombinant human BPIFA1 (rhBPIFA1). Noncultured nasal cells with the rs750064 CC
genotype had significantly less BPIFA1 mRNA expression than the CT and TT genotypes.
Cultured CC versus CT and TT cells without stimulation maintained less BPIFA1
expression. With IL-13 treatment, CC genotype cells secreted more eotaxin-3 than CT and
TT genotype cells. Also, rhBPIFA1 reduced IL-13–mediated eotaxin-3. BPIFA1 mRNA
levels negatively correlated with serum IgE and fractional exhaled nitric oxide. Baseline
FEV1% levels were lower in the asthma patients with the CC genotype (n = 1,016). Our data
suggest that less BPIFA1 in asthma patients with the CC allele may predispose them to
greater eosinophilic inflammation, which could be attenuated by rhBPIFA1 protein therapy.
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Introduction
Asthma is a heterogeneous disease that has at least 2 broad endotypes: type 2 high and type 2 low. Patients 
with type 2–high asthma have higher levels of  type 2 cytokines, such as IL-13, IL-4, and IL-5, which are 
associated with higher levels of  IgE, eosinophils, and periostin (1–3). How airway innate immunity regulates 
type 2 inflammation remains a topic of  interest. Because airway epithelium serves as a critical first line of  
host innate immunity, previous research has focused on its role in type 2 inflammation. Bacterial permeabili-
ty family member A1 (BPIFA1), also known as short palate, lung, and nasal epithelium clone 1 (SPLUNC1), 
is a secretory protein primarily produced by airway (nasal, bronchial) epithelium (4–7). BPIFA1 has been 
reported to exert antiinflammatory properties during microbial infections and Toll-like receptor agonist 
stimulation (8–13). We and others (14–16) have found that IL-13 and allergen challenges significantly reduce 
airway epithelial expression of  BPIFA1, which in turn further exaggerates type 2 inflammation (16).
The impact of  genetic variation on BPIFA1 expression in asthmatic airway epithelium has not been 
investigated. An early study in a Chinese population (17) suggests that single nucleotide polymorphisms 
(SNPs) of  BPIFA1 (e.g., the rs750064 CC genotype) were associated with increased susceptibility to naso-
pharyngeal carcinoma. A recent study in cystic fibrosis (CF) patients’ lungs (18) demonstrated that the 
minor allele G of  rs1078761 located in exon 3 of  long PLUNC1 (LPLUNC1) reduced lung function and 
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expression of  LPLUNC1 as well as BPIFA1. However, there is a minimal effect of  rs750064 on lung tissue 
BPIFA1 expression in CF. Of  note, these studies did not specifically examine BPIFA1 in airway epithelial 
cells, the major source of  BPIFA1.
In the current study, we hypothesized that BPIFA1 expression is partly controlled by genetic variations, 
which affect the epithelial response to type 2 cytokines. To test this hypothesis, we obtained nasal brush-
ing samples from subjects with asthma participating in the National Heart, Lung, and Blood Institute–
sponsored (NHLBI-sponsored) Severe Asthma Research Program 3 (SARP3). We genotyped rs750064, 
measured BPIFA1 expression by nasal epithelial cells, and performed air-liquid interface culture of  nasal 
epithelial cells carrying different alleles of  rs750064 to determine the effect of  BPIFA1 genetic variation on 
IL-13–mediated production of  proeosinophilic mediator eotaxin-3 (CCL26). We also tested the therapeutic 
effect of  recombinant human BPIFA1 protein on IL-13–mediated eotaxin-3. Additionally, we correlated 
BPIFA1 expression with type 2 markers and pulmonary function in patients with asthma.
Results
Unlike the invasive nature of  bronchoscopy used to obtain the brushed bronchial epithelial cells, nasal 
brushing is considered minimally invasive and can be done in adults and children. Moreover, nasal epi-
thelial cells were shown to demonstrate similar gene expression pattern to bronchial epithelial cells (19). 
To determine whether BPIFA1 expression in nasal epithelial cells may predict that in bronchial epithelial 
cells, in a pilot study, we analyzed RNA sequencing data of  brushed nasal and bronchial epithelial cells 
(time of  sampling, noncultured) obtained from the same healthy subjects (n = 7) and stable subjects with 
asthma (n = 9) (ages, 19–52 years). Supplemental Figure 1 (supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.127237DS1) demonstrates a strong positive correlation 
between BPIFA1 mRNA expression in nasal and bronchial epithelial cells. Thus, nasal brushing may serve 
as a robust and minimally invasive approach to study BPIFA1 expression in asthma.
Variant rs750064 affects BPIFA1 expression in brushed asthmatic nasal epithelial cells
BPIFA1 mRNA expression levels in brushed (noncultured) nasal epithelial cells were compared in 74 adult 
and pediatric subjects with asthma (49 adult, Table 1; 25 pediatric, Table 2). As shown in Figure 1A, BPI-
FA1 mRNA levels in nasal epithelial cells expressing the CC genotype (n = 27) were about 30-fold lower (P 
< 0.0001) than those expressing the CT (n = 34) or TT (n = 13) genotype. Interestingly, BPIFA1 mRNA lev-
els were similar between the cells expressing the CT or TT genotype, suggesting the T allele as the dominant 
allele and the C allele as the recessive allele. BPIFA1 mRNA expression levels were similar among adult and 
pediatric subjects with asthma, as well as in those with severe versus nonsevere asthma.
To test whether differential expression of  BPIFA1 by genotypes in noncultured, brushed cells can be 
maintained in cultured cells, BPIFA1 mRNA expression was analyzed in expanded nasal epithelial cells 
under the submerged culture without any treatment. Once again, the CC genotype showed significantly less 
Table 1. Demographic information of adult subjects with asthma from the SARP3 cohort
rs750064 CC CT TT
N 17 24 8
Race (White/African American) 10/7 23/1 8/0
Sex (male/female) 8/9 8/16 2/6
Age (yrs) 45.0 ± 13.6 50.5 ± 16.8 45.7 ± 14.9
Age of asthma onset (yrs) 17.5 ± 15.5 18.2 ± 16.8 16.7 ± 14.2
Asthma severity 8 mild/moderate, 9 severe 8 mild/moderate, 16 severe 2 mild/moderate, 6 severe
No. of exacerbations  
(within last 12 months)
0.9 ± 1.6 0.9 ± 1.3 0.8 ± 0.7
FEV1/FVC 0.68 ± 0.11 0.73 ± 0.10 0.73 ± 0.11
FEV1 (%) 83.9 ± 17.9 92.8 ± 22.6 87.3 ± 15.3
% on ICS 64.7 66.7 62.5
% on other CS 17.6 58.3 12.5
BMI 30.2 ± 7.4 31.4 ± 7.9 31.9 ± 6.9
FVC, forced vital capacity; ICS, inhaled corticosteroids; other CS, oral/injected corticosteroids. BMI, body mass index (kg/m2).
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BPIFA1 mRNA expression than the CT and TT genotypes (Figure 1B). Expression of  BPIFA1 mRNA was 
measured after nasal epithelial cells underwent 16 days of  air-liquid interface (ALI) culture (mucociliary 
differentiation), and again subjects with the CC genotype maintained significantly lower BPIFA1 mRNA 
expression (Figure 1C).
Functional implication of rs750064 in the cultured human nasal epithelial response to 
IL-13 treatment
The effect of  rs750064 on BPIFA1 protein expression in nasal epithelial cells cultured at the ALI. After 16 days of  
mucociliary differentiation, BPIFA1 protein levels were significantly lower in the CC genotype than the CT 
and TT genotypes in the absence of  IL-13 (Figure 2). IL-13 significantly reduced BPIFA1 levels in all the 
genotypes as previously reported (14–16).
The effect of  rs750064 on nasal epithelial proinflammatory responses to IL-13 treatment. Eotaxin-3 in baso-
lateral supernatants of  ALI-cultured nasal epithelial cells was measured by ELISA to determine whether 
rs750064-dependent BPIFA1 expression affects the epithelial proinflammatory response to IL-13. Eotax-
in-3 was significantly induced by IL-13 treatment as previously reported (20, 21). Cells with the CC geno-
type were significantly more responsive to IL-13 treatment, because they had higher eotaxin-3 levels than 
the CT and TT genotypes (Figure 3A).
Recombinant human BPIFA1 protein inhibits the proinflammatory response to IL-13 treatment. The addition of  
recombinant human BPIFA1 (rhBPIFA1) protein into the apical surface of  nasal epithelial cells cultured at 
the ALI significantly decreased IL-13–induced eotaxin-3 production in cells carrying both CC and CT or 
TT genotypes, leaving both genotypes with similar eotaxin-3 levels (Figure 3B). The CC genotype showed 
a 140-fold reduction in eotaxin-3 levels after rhBPIFA1 treatment, compared with a 100-fold reduction in 
the CT and TT genotypes.
Type 2 inflammation signatures in brushed nasal epithelial cells carrying different 
genotypes of rs750064
Because BPIFA1 deficiency leads to greater type 2 inflammation in mice challenged with ovalbumin 
(16), we determined whether nasal cells expressing the CC genotype demonstrated enhanced type 2 
signatures, such as periostin and eotaxin (22–24). Periostin mRNA levels tended to be higher in cells 
expressing the CC genotype than those expressing the CT or TT genotype (Figure 4A) and were nega-
tively correlated with BPIFA1 levels, as shown in Figure 4B. When race was considered, the correlation 
of  SPLUNC1 with periostin mRNA was more significant in the White subjects than African Americans 
after adjustment for age and sex. Eotaxin-3, an eosinophil chemoattractant, was measured in the non-
cultured nasal epithelial cells. The cells carrying the CC genotype showed slightly higher median eotax-
in-3 mRNA levels (P = 0.09) than those carrying the CT and TT genotypes (Figure 4C).
Table 2. Demographic information of pediatric subjects with asthma from the SARP3 cohort
rs750064 CC CT TT
N 10 10 5
Race (White/African American) 2/9 9/1 5/0
Sex (male/female) 6/5 5/5 3/2
Age (yrs) 12.6 ± 1.5 12.5 ± 2.1 13.6 ± 2.0
Age of asthma onset (yrs) 1.8 ± 1.9 2.0 ± 2.4 3.3 ± 2.8
Asthma severity 6 mild/moderate, 4 severe 6 mild/moderate, 4 severe 4 mild/moderate, 1 severe
No. of exacerbations  
(within last 12 months)
0.7 ± 1.3 0.5 ± 1.0 1.6 ± 2.1
FEV1/FVC 0.76 ± 0.08 0.80 ± 0.11 0.72 ± 0.03
FEV1 (%) 108.8 ± 7.1 101.8 ± 12.9 105.5 ± 13.5
% on ICS 80 60 20
% on other CS 50 60 80
BMI 20.4 ± 1.8 22.7 ± 4.6 25.9 ± 6.3
FVC, forced vital capacity; ICS, inhaled corticosteroids; other CS, oral/injected corticosteroids; BMI, body mass index (kg/m2).
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Correlations of BPIFA1 expression with blood and airway type 2 biomarkers as well as 
pulmonary function
We examined the relationship of nasal epithelial BPIFA1 expression to blood and airway type 2 biomarkers, 
such as serum IgE, fractional exhaled nitric oxide (FeNO), and blood eosinophils. BPIFA1 mRNA levels in nasal 
brushings collected from subjects in the SARP3 study cohort were inversely (P < 0.05) correlated to serum IgE 
(Figure 5A) and FeNO levels (Figure 5B). Because there appeared to be several outliers of serum IgE and FeNO 
data, we further analyzed the data without these outliers and found that the significance of correlations between 
BPIFA1 mRNA and serum IgE and FeNO was reduced (P > 0.05). Although both serum IgE and FeNO were 
numerically higher in the CC group than the CT and TT groups, the differences were not statistically different. 
There was no significant correlation between nasal epithelial BPIFA1 expression and number of blood eosino-
phils in all the subjects expressing different BPIFA1 genotypes (r = 0.06, P = 0.62). Patients with asthma carrying 
the CC genotype showed marginally higher levels of eosinophils in induced sputum (Supplemental Figure 2), 
but not blood (data not shown) samples, than those carrying the CT and TT genotypes.
In 1,016 asthma subjects (non-Hispanic White) enrolled in the SARP1, SARP2, and SARP3 cohorts 
(Table 3), the rs750064 SNP was significantly associated with baseline FEV1% levels (nominal P = 0.045) 
with adjustment for age, sex, and genetic ancestry (principal components 1–5 calculated based on sequencing 
data), where the CC genotype had significantly lower FEV1% levels compared with the other 2 genotypes. 
However, in the population of  African Americans with asthma, FEV1% levels were not significantly different 
among the rs750064 genotypes (data not shown).
There were no significant associations between rs750064 and the other clinical data, including asthma 
severity, age of  asthma onset, the frequency of  asthma exacerbations over the previous 12 months, and BMI.
Figure 1. Subjects with the rs750064 CC genotype have significantly less 
BPIFA1 mRNA expression than subjects with the CT and TT genotypes. 
BPIFA1 mRNA expression was measured from (A) noncultured nasal 
epithelial cells of 74 mild to severe subjects with asthma (n = 49 adults, 
n = 25 children), (B) expanded (submerged culture for 10 days) nasal 
epithelial cells from 37 asthmatics (n = 33 adults, n = 4 children) without 
any stimulation, and (C) differentiated (ALI culture for 14 days) mucocil-
iary nasal epithelial cells from subjects with various genotypes (10 CC: 8 
White, 2 African American; 8 CT: 8 White, 0 African American; and 4 TT: 
4 White, 0 African American) without any stimulation. P values from A 
represent a linear regression additive genetic model with adjustments for 
age, sex, and race; B represents a Kruskal-Wallis test; and C represents a 
Mann-Whitney test. The black line represents the median value.
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Although no healthy controls were enrolled in the SARP3 cohort for the nasal brushing study, we were 
able to analyze the correlation of  rs750064 with pulmonary function in normal subjects recruited in the 
SARP1 and SARP2 cohorts. Unlike in the patients with asthma, similar FEV1% (P > 0.05) values were 
observed in normal, healthy non-Hispanic Whites (Table 4) as well as African Americans (not shown).
Discussion
Our study shows that BPIFA1 expression in asthmatic nasal epithelium is in part controlled by the genetic 
variations related to the rs750064 SNP, where the CC genotype has lower BPIFA1 than the CT and TT 
genotypes. Our potentially novel findings from nasal epithelial cells suggest the strong predictability of  
rs750064 genotypes in airway BPIFA1 expression. We propose that this genetic variability in airway cell 
expression of  BPIFA1 in subjects with asthma may predispose them to greater eosinophilic inflammation, 
a feature associated with type 2 inflammation.
Within the BPIFA1 gene, rs750064 is located in the promoter region. Whether rs750064-related BPI-
FA1 expression is stable from an in vivo to an in vitro setting has not been investigated. Because our 
preliminary study (Supplemental Figure 1) demonstrated a significantly positive correlation of  BPIFA1 
mRNA expression in human nasal and bronchial epithelial cells, our data further support the use of  nasal 
brushings as a minimally invasive approach to bronchial brushings in the study of  epithelial cell func-
tions related to the BPIFA1 protein. By examining BPIFA1 expression in nasal epithelial cells collected 
at the time of  brushing, and cultured under both undifferentiated (submerged) and differentiated (ALI) 
conditions, we found that BPIFA1 expression is highly dependent on the rs750064 genotypes, where the 
CC genotype cells expressed the lowest levels of  BPIFA1. Of  note, the nasal epithelial cells collected 
in vivo and cultured at the ALI expressed more BPIFA1 than the undifferentiated nasal epithelial cells. 
These data further support the concept that secretory cells may be the major producer of  BPIFA1, which 
needs further confirmation using the single-cell RNA sequencing approach. To determine the impact 
of  rs750064 on BPIFA1 expression under a pathological condition, type 2 cytokine IL-13 was added to 
well-differentiated nasal epithelial cells. Similar to our previous work (and the work of  others) (14, 15, 
25, 26), IL-13 significantly reduced BPIFA1 expression, suggesting the contribution of  both genetic and 
environmental factors to BPIFA1 expression. However, because of  the overwhelmingly inhibitory effect 
of  IL-13 on BPIFA1 expression in vitro, the genetic impact of  rs750064 on BPIFA1 levels was minimal 
when IL-13 was present. Our selection of  the IL-13 dose (10 ng/ml) is extensively used in the literature 
(14, 21, 27, 28). Nevertheless, it would be interesting to use lower doses of  IL-13 in future studies to 
determine whether the rs750064 CC genotype affects the sensitivity to the suppressing effect of  IL-13 on 
BPIFA1 in airway epithelial cells.
Figure 2. BPIFA1 protein levels remain significantly lower in CC genotypes after 16 days of ALI culture. Nasal epithe-
lial cells with the rs750064 CC genotype have significantly lower levels of BPIFA1 protein than the CT and TT genotypes. 
IL-13 treatment significantly reduces BPIFA1 protein. The P values represent a Kruskal-Wallis test. The gray squares and 
black triangles represent the CT and TT genotype, respectively. The black line represents the median value. n = 10 CC (8 
White, 2 African American); n = 8 CT (8 White, 0 African American) and n = 4 TT (4 White, 0 African American).
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We found that low BPIFA1 levels modestly predicted the degree of  type 2 inflammation reflected by 
periostin and eotaxin-3 in nasal epithelial cells, serum IgE, and FeNO. The relatively weak correlations 
of  BPIFA1 mRNA and type 2 markers in the current study may be in part explained by the fact that 
these subjects are in the stable phase of  disease. Eosinophils in the blood and sputum have been used as 
a marker of  type 2 inflammation (1, 2, 29). In our current study, asthmatics carrying the CC genotype 
had marginally higher levels of  eosinophils in induced sputum, but not blood samples, than those carry-
ing the CT and TT genotypes. Once again, this may be due to less active inflammation during the stable 
phase of  the disease. This speculation was supported by the observation that when differentiated nasal 
epithelial cells were treated with IL-13 to mimic a type 2–high airway, eotaxin-3 was significantly higher 
in the CC genotype (P < 0.05). Moreover, ovalbumin-challenged, BPIFA1-deficient mice demonstrated 
exaggerated airway eosinophilic inflammation (16). Together, our data suggest that reduced BPIFA1 
levels may predispose the airways to more robust eosinophilic inflammation in vivo. However, how 
BPIFA1 regulates eosinophilic inflammation is unclear. Although we focused on the inhibitory effect of  
BPIFA1 on eotaxin production, the exact signaling pathways need to be further examined.
Although FEV1% in the SARP3 subjects expressing the CC genotype tended to be less than the percentage 
in the other 2 genotypes, it was not statistically significant. However, by using the subjects recruited from the 
3 SARP cohorts, we found a significant baseline reduction in FEV1% levels in non-Hispanic, White patients 
with asthma carrying the CC genotype. Therefore, rs750064 appears to have a marginal impact on baseline 
lung function, because BPIFA1 levels did not affect disease severity. This may be in part explained by the fact 
that the subjects included in this report were stable and not experiencing an acute asthma exacerbation.
There are some limitations to our study. First, the current study did not directly address how rs750064 
affects BPIFA1 transcription or translation. Second, there are multiple BPIFA1 SNPs (17), and whether 
those additional BPIFA1 genetic variations affect its expression and function remains to be determined. 
Last, because the focus of  the SARP3 cohort was on enrolling asthmatics, only nasal epithelial cells from 
the subjects with asthma were available to our study. Future studies are warranted to recruit normal, 
healthy subjects to clarify whether rs750064-related differences in BPIFA1 expression and functions are 
restricted to asthma. Nonetheless, in our pilot study, we measured BPIFA1 mRNA expression of  noncul-
tured nasal brushing cells obtained from 15 nonasthmatic subjects who did not have a known lung disease 
(n = 5) or were diagnosed with other lung diseases (n = 10), such as sarcoidosis. We found that like the 
asthmatic subjects, nonasthmatic subjects with the rs750064 CC genotype expressed lower levels of  BPI-
FA1 mRNA than those expressing the other 2 genotypes (Supplemental Figure 3). Thus, a combination of  
rs750064 and other factors (genetic and environmental) may eventually determine asthma pathobiology.
Figure 3. Eotaxin-3 induction by IL-13 is more robust in rs750064 CC genotype cells. (A) In asthmatic nasal epithelial cells cultured at the ALI, IL-13–
induced eotaxin-3 levels are significantly higher in the rs750064 CC genotype cells than the CT and TT genotype cells (n = 10 for CC: 8 White, 2 African 
American; n = 8 CT: 8 White, 0 African American; n = 4 for TT: 4 White, 0 African American). The P value represents the Mann-Whitney test. The black line 
represents the median value. (B) For all rs750064 genotypes, rhBPIFA1 protein significantly inhibits IL-13–induced eotaxin-3 (n = 7 CC: 5 White, 2 African 
American; n = 6 CT: 6 White, 0 African American, and n = 2 TT: 2 White, 0 African American). The P values for indicated comparisons represent a Krus-
kal-Wallis test. The gray squares and black triangles represent the CT and TT genotypes, respectively. The black line represents the median value.
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In summary, our study has shown a significant impact of  genetic variations on BPIFA1 expres-
sion in the minimally invasive nasal brushing samples from patients with asthma. The interactions of  
genetically predetermined BPIFA1 expression within a type 2 airway milieu may form a vicious cycle 
in worsening airway inflammation. BPIFA1-targeted therapy may offer a novel opportunity to reduce 
type 2 inflammation in a subset of  patients with asthma expressing lower levels of  BPIFA1 associated 
with rs750064.
Methods
Subject recruitment. Nonsmoking (<10 pack years and no smoking in past year) patients with asthma were 
recruited in SARP cohorts 1, 2, and 3. The categorization of  severe asthma was based on the European 
Respiratory Society and American Thoracic Society guidelines (30). Briefly, severe asthma was defined as 
that requiring the use of  high-dose inhaled and/or oral corticosteroids, along with a second controller, to keep 
the asthma controlled or remaining uncontrolled despite therapy. Evaluations included pulmonary function 
testing, total serum IgE, white blood cell counts and differentials, and FeNO measurements (31, 32).
Subjects who did not meet the criteria for severe asthma were divided into mild or moderate asthma on 
the basis of  lung function and inhaled corticosteroid (ICS) use (32). Mild asthma was defined as an FEV1 
of  greater than 80% with little to no ICS use (32). Moderate asthma was defined as an FEV1 of  less than 
80% with low to moderate ICS use (32).
Figure 4. Effect of rs750064 genotypes on type 2 markers. (A) Periostin mRNA expression (n = 26 for CC; n = 34 for CT; and n = 13 for TT). (B) A neg-
ative correlation of BPIFA1 mRNA with periostin mRNA in noncultured nasal brushing cells from 73 subjects with asthma (n = 48 adults, n = 25 chil-
dren) using a Pearson’s correlation analysis. (C) Eotaxin-3 mRNA expression (n = 26 for CC; n = 34 for CT; and n = 13 for TT). The black line represents 
the median value, and the Mann-Whitney test was used for A and C.
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Nasal brushing samples and clinical outcomes from 74 subjects of  the SARP3 cohort were used in this 
study. SARP3 is the most current cohort, for which 118 pediatric (ages 6 to 17 years old) and 526 adult (18 
years and older) subjects with asthma were recruited (33).
To further define the implication of  BPIFA1 genetic variations in clinical outcomes, data from 1,016 
asthma subjects previously included in the genome-wide association studies (GWAS) from all 3 SARP 
cohorts were analyzed. Additionally, 123 healthy controls from the SARP1 and SARP2 cohorts, as report-
ed in our previous study (34), were included.
Nasal brush collection. Nasal brushing epithelial cells (n = 74) were collected from mild to severe adult 
(n = 50, Table 1) and pediatric (n = 24, Table 2) patients with asthma. Each subject underwent 2 nasal 
brushings, 1 per nostril. A cytology brush was inserted into the nasal cavity just past the inferior turbinate 
and then rolled laterally so that the epithelium just under the inferior turbinate was brushed (19). Once col-
lected, 1 nasal brush was put in a collection tube containing freezing media (60% DMEM, 30% FBS, 10% 
DMSO), which was later used for epithelial cell culture, and the other brush was placed into a collection 
tube containing Qiagen RLT Plus buffer and 2 M DTT (MilliporeSigma) and then extracted for DNA and 
RNA extraction using a Qiagen AllPrep DNA/RNA Mini Kit.
Detection of  rs750064 SNP alleles. BPIFA1 rs750064 in nasal brushing samples was genotyped by 
sequencing the region flanking rs750064. Genomic DNA, isolated from noncultured brushed nasal epi-
thelial cells, was first amplified by PCR to generate a 339-bp DNA fragment spanning the SNP region 
using high-fidelity DNA polymerase and the following specific oligonucleotide primers: 5′-GGGGCCAA-
Figure 5. Association of nasal epithelial BPIFA1 mRNA expression with type 2 markers in clinical samples. (A) Correlation of BPIFA1 mRNA levels with 
serum IgE levels (n = 74). (B) Correlation of BPIFA1 mRNA levels with FeNO, parts per billion (ppb), levels (n = 73) in asthmatic subjects with mild to severe 
disease. A Pearson’s correlation analysis was performed.
Table 3. Demographic information of subjects with asthma (non-Hispanic Whites) from the SARP1, SARP2, and SARP3 cohorts
rs750064 CC CT TT
N 237 514 265
Sex (male/female) 96/141 174/340 90/175
Age (yrs) 38.6 ± 16.7 39.0 ± 17.0 40.5 ± 16.6
Age of asthma onset (yrs) 14.9 ± 14.7 15.9 ± 16.0 18.1 ± 15.7
Asthma severity 136 mild/moderate, 101 severe 281 mild/moderate, 232 severe 147 mild/moderate, 118 severe
FEV1/FVC 0.71 ± 0.12 0.72 ± 0.12 0.72 ± 0.12
FEV1 (%) 76.0 ± 21.6A 77.4 ± 21.5 78.8 ± 21.1
% on ICS 80 80 79
% on other CS 23 18 20
BMI 28.8 ± 7.6 28.9 ± 7.9 29.3 ± 8.1
AP < 0.05. FVC, forced vital capacity; ICS, inhaled corticosteroids; other CS, oral/injected corticosteroids; BMI, body mass index (kg/m2).
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GAGATGAGACTG-3′ (forward primer) and 5′-CTCACTTCTGCCGAGGAGTC-3′ (reverse primer). 
The resulting DNA fragment was purified by agarose gel electrophoresis and extracted from the gel as a sin-
gle band using QIAquick Gel Extraction Kit (Qiagen). The purified product was then subjected to Sanger 
sequencing using the following internal oligonucleotide primer: 5′-TGAGACTGAGGTCCCTTCCT-3′. 
Reference genomic DNA samples containing either one of  the SNP variants were obtained from Coriell 
Institute for Medical Research (Camden, New Jersey) and were used as controls for each variant. These 
included reference samples NA07348 (CC genotype), NA10831 (CT genotype), and NA06990 (TT geno-
type). The allelic frequency within the study population was 0.5946 for the C allele and 0.4054 for the T 
allele. These allelic frequencies are representative of  the normal population distribution (35).
BPIFA1 rs750064 in the SARP1, 2, and 3 cohorts was identified with the Illumina Human Hap1M 
BeadChip (34).
ALI culture of  nasal epithelial cells. Nasal epithelial cells were cultured and expanded on irradiated 
3T3 fibroblasts (ATCC) in the presence of  a Rho kinase inhibitor Y-27632 as described previously (36, 
37). Nasal epithelial cells from 22 patients with asthma (10 CC, 8 CT, 4 TT) chosen randomly, 11 to 
66 years of  age and ranging in severity from mild to severe, were seeded onto collagen-coated, 12-well 
Transwell plates (Transwell 3460, Corning Incorporated) at 4 × 104 cells/well in medium made up of  
DMEM and Airway Epithelial Cell Growth Media Kit (PromoCell) (1:1). After 7 days of  submerged 
culture, 100% confluence was reached, and the cells were shifted to ALI by removing all but 50 μl of  
medium from the apical surface to induce mucociliary differentiation. Cells were allowed to differenti-
ate for 14 days, which was based on our previous work where cilia were enriched after 14 days of  ALI 
(20, 21, 38). On day 14 of  ALI culture, cells were pretreated with 10 ng/ml of  IL-13 (R&D Systems) 
and/or 20 μg/ml of  rhBPIFA1 protein or BSA (control) for 24 hours. Following the 24-hour pretreat-
ment the cells were again treated with 10 ng/ml of  IL-13 and/or 20 μg/ml of  rhBPIFA1 protein. Cells 
and supernatants were harvested 24 hours later. Briefly, 200 μl of  Dulbecco’s PBS (Thermo Fisher Sci-
entific) was added to the apical surface and incubated at 37°C for 10 minutes, after which both apical 
and basolateral supernatants were collected. Our group produced and purified rhBPIFA1 protein as 
described previously (16).
Enzyme-linked immunosorbent assay. BPIFA1 protein levels in the apical supernatant were measured 
using a direct BPIFA1 ELISA that we developed (14). Eotaxin-3 protein levels from the basolateral super-
natants were measured using a DuoSet ELISA kit from R&D Systems.
Quantitative real-time PCR. RNA from noncultured or cultured nasal epithelial cells was extracted using 
the RNeasy Mini Kit (Qiagen). We performed reverse transcription on 500 ng of  RNA to produce cDNA 
using the Bio-Rad T100 thermal cycler.
TaqMan gene expression assay for human eotaxin-3 and periostin was obtained from Thermo Fisher 
Scientific, and a custom-made gene expression assay for human BPIFA1 was obtained from Integrated 
DNA Technologies (14). The housekeeping gene 18S rRNA was used as an internal control to normalize 
the expression of  target genes. The comparative cycle of  threshold (ΔΔCt) method was used to demonstrate 
the relative levels of  the target genes.
Statistics. One-way ANOVA followed by a Tukey’s post hoc test was used for multiple comparisons 
of  normally distributed data. Two-tailed Student’s t test was used when only 2 groups were compared. 
For nonparametric data, the Mann-Whitney test was used when only 2 groups were compared, and the 
Kruskal-Wallis test was applied for multiple comparisons. Pearson’s correlation analysis was performed 
to determine the relationship of  various parameters as reported in the Results section. A linear regression 
Table 4. Demographic information of 123 healthy controls (non-Hispanic Whites) from SARP1 and SARP2 cohorts
rs750064 CC CT TT
N 30 68 25
Sex 8 male, 22 female 26 male, 42 female 9 male, 16 female
Age (yrs) 30.8 ± 11.2 32.9 ± 12.0 31.0 ± 9.3
FEV1/FVC 0.83 ± 0.07 0.82 ± 0.07 0.80 ± 0.07
FEV1 (%) 99.3 ± 11.2 97.9 ± 10.8 97.4 ± 10.3
FVC, forced vital capacity.
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additive genetic model with adjustment of  age, sex, and race (34) was used to determine the association of  
rs750064 with BPIFA1 expression and pulmonary function (e.g., FEV1%). A P value less than 0.05 was 
considered significant.
Study approval. Research subjects were recruited at 5 SARP centers. Each center had the IRB approval 
to enroll the subjects with asthma into the SARP cohort and perform the nasal brushings. All the adult 
subjects or the parents/guardians of  the children provided written informed consent (32).
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